"use strict";(self.webpackChunkbiopath_docs=self.webpackChunkbiopath_docs||[]).push([[5427],{6119:(e,n,i)=>{i.r(n),i.d(n,{assets:()=>o,contentTitle:()=>a,default:()=>h,frontMatter:()=>t,metadata:()=>s,toc:()=>c});const s=JSON.parse('{"id":"investment/exit-strategy","title":"Exit Strategy","description":"Overview","source":"@site/docs/investment/exit-strategy.md","sourceDirName":"investment","slug":"/investment/exit-strategy","permalink":"/docs/investment/exit-strategy","draft":false,"unlisted":false,"editUrl":"https://github.com/biopath/biopath-docs/tree/main/docs/investment/exit-strategy.md","tags":[],"version":"current","lastUpdatedBy":null,"lastUpdatedAt":null,"sidebarPosition":6,"frontMatter":{"sidebar_position":6}}');var r=i(4848),l=i(8453);const t={sidebar_position:6},a="Exit Strategy",o={},c=[{value:"Overview",id:"overview",level:2},{value:"Exit Options Analysis",id:"exit-options-analysis",level:2},{value:"Strategic Acquisition",id:"strategic-acquisition",level:3},{value:"Pharmaceutical Companies",id:"pharmaceutical-companies",level:4},{value:"Biotech Companies",id:"biotech-companies",level:4},{value:"Wellness Companies",id:"wellness-companies",level:4},{value:"Private Equity Acquisition",id:"private-equity-acquisition",level:4},{value:"Initial Public Offering (IPO)",id:"initial-public-offering-ipo",level:3},{value:"Public Market Readiness",id:"public-market-readiness",level:4},{value:"IPO Valuation",id:"ipo-valuation",level:4},{value:"IPO Requirements",id:"ipo-requirements",level:4},{value:"Exit Timeline and Milestones",id:"exit-timeline-and-milestones",level:2},{value:"Years 1-2: Foundation Building",id:"years-1-2-foundation-building",level:3},{value:"Years 3-4: Market Expansion",id:"years-3-4-market-expansion",level:3},{value:"Years 5-6: Scale and Optimization",id:"years-5-6-scale-and-optimization",level:3},{value:"Years 7-8: Exit Execution",id:"years-7-8-exit-execution",level:3},{value:"Valuation Analysis",id:"valuation-analysis",level:2},{value:"Revenue-Based Valuation",id:"revenue-based-valuation",level:3},{value:"Current Market Multiples",id:"current-market-multiples",level:4},{value:"Company-Specific Factors",id:"company-specific-factors",level:4},{value:"Comparable Company Analysis",id:"comparable-company-analysis",level:3},{value:"Public Company Comparables",id:"public-company-comparables",level:4},{value:"Private Company Transactions",id:"private-company-transactions",level:4},{value:"DCF Valuation Model",id:"dcf-valuation-model",level:3},{value:"Key Assumptions",id:"key-assumptions",level:4},{value:"Valuation Range",id:"valuation-range",level:4},{value:"Strategic Buyer Analysis",id:"strategic-buyer-analysis",level:2},{value:"Pharmaceutical Companies",id:"pharmaceutical-companies-1",level:3},{value:"Novartis",id:"novartis",level:4},{value:"Pfizer",id:"pfizer",level:4},{value:"Johnson &amp; Johnson",id:"johnson--johnson",level:4},{value:"Private Equity Firms",id:"private-equity-firms",level:3},{value:"KKR (Healthcare Growth)",id:"kkr-healthcare-growth",level:4},{value:"Blackstone (Life Sciences)",id:"blackstone-life-sciences",level:4},{value:"Exit Process Management",id:"exit-process-management",level:2},{value:"Preparation Phase (12-18 months)",id:"preparation-phase-12-18-months",level:3},{value:"Financial Preparation",id:"financial-preparation",level:4},{value:"Operational Preparation",id:"operational-preparation",level:4},{value:"Legal Preparation",id:"legal-preparation",level:4},{value:"Marketing Phase (6-9 months)",id:"marketing-phase-6-9-months",level:3},{value:"Investment Banking Selection",id:"investment-banking-selection",level:4},{value:"Marketing Materials",id:"marketing-materials",level:4},{value:"Buyer Outreach",id:"buyer-outreach",level:4},{value:"Execution Phase (3-6 months)",id:"execution-phase-3-6-months",level:3},{value:"Due Diligence Management",id:"due-diligence-management",level:4},{value:"Negotiation and Closing",id:"negotiation-and-closing",level:4},{value:"Value Maximization Strategies",id:"value-maximization-strategies",level:2},{value:"Strategic Positioning",id:"strategic-positioning",level:3},{value:"Market Leadership",id:"market-leadership",level:4},{value:"Financial Performance",id:"financial-performance",level:4},{value:"Operational Excellence",id:"operational-excellence",level:4},{value:"Timing Optimization",id:"timing-optimization",level:3},{value:"Market Conditions",id:"market-conditions",level:4},{value:"Company Readiness",id:"company-readiness",level:4},{value:"Risk Mitigation",id:"risk-mitigation",level:2},{value:"Exit Risk Factors",id:"exit-risk-factors",level:3},{value:"Market Risks",id:"market-risks",level:4},{value:"Company-Specific Risks",id:"company-specific-risks",level:4},{value:"Mitigation Strategies",id:"mitigation-strategies",level:3},{value:"Diversification",id:"diversification",level:4},{value:"Contingency Planning",id:"contingency-planning",level:4},{value:"Post-Exit Considerations",id:"post-exit-considerations",level:2},{value:"Stakeholder Alignment",id:"stakeholder-alignment",level:3},{value:"Investor Returns",id:"investor-returns",level:4},{value:"Management Team",id:"management-team",level:4},{value:"Employee Considerations",id:"employee-considerations",level:4},{value:"Integration Planning",id:"integration-planning",level:3},{value:"Strategic Acquisitions",id:"strategic-acquisitions",level:4},{value:"Financial Buyers",id:"financial-buyers",level:4},{value:"Next Steps",id:"next-steps",level:2},{value:"Immediate Actions (Next 12 Months)",id:"immediate-actions-next-12-months",level:3},{value:"Medium-Term Preparation (Years 2-3)",id:"medium-term-preparation-years-2-3",level:3},{value:"Exit Execution (Years 4-5)",id:"exit-execution-years-4-5",level:3}];function d(e){const n={h1:"h1",h2:"h2",h3:"h3",h4:"h4",header:"header",li:"li",ol:"ol",p:"p",strong:"strong",ul:"ul",...(0,l.R)(),...e.components};return(0,r.jsxs)(r.Fragment,{children:[(0,r.jsx)(n.header,{children:(0,r.jsx)(n.h1,{id:"exit-strategy",children:"Exit Strategy"})}),"\n",(0,r.jsx)(n.h2,{id:"overview",children:"Overview"}),"\n",(0,r.jsx)(n.p,{children:"This document outlines the comprehensive exit strategy for a peptide therapy business, including exit options, timing considerations, valuation analysis, and strategic preparation for maximizing investor returns."}),"\n",(0,r.jsx)(n.h2,{id:"exit-options-analysis",children:"Exit Options Analysis"}),"\n",(0,r.jsx)(n.h3,{id:"strategic-acquisition",children:"Strategic Acquisition"}),"\n",(0,r.jsx)(n.h4,{id:"pharmaceutical-companies",children:"Pharmaceutical Companies"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Target Acquirers"}),": Novartis, Pfizer, Johnson & Johnson, Merck"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Rationale"}),": Portfolio expansion, market access, technology acquisition"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Valuation Multiple"}),": 4-8x revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Timeline"}),": 5-7 years from Series A"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Probability"}),": High (70-80%)"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"biotech-companies",children:"Biotech Companies"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Target Acquirers"}),": Amgen, Gilead, Biogen, Regeneron"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Rationale"}),": Complementary technologies, market expansion"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Valuation Multiple"}),": 3-6x revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Timeline"}),": 4-6 years from Series A"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Probability"}),": Medium (40-60%)"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"wellness-companies",children:"Wellness Companies"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Target Acquirers"}),": Thorne Health, Life Extension, Designs for Health"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Rationale"}),": Product portfolio expansion, customer base"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Valuation Multiple"}),": 2-4x revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Timeline"}),": 3-5 years from Series A"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Probability"}),": Medium (30-50%)"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"private-equity-acquisition",children:"Private Equity Acquisition"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Target Acquirers"}),": KKR, Blackstone, TPG (healthcare-focused)"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Rationale"}),": Platform for consolidation, growth acceleration"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Valuation Multiple"}),": 3-5x revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Timeline"}),": 4-6 years from Series A"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Probability"}),": Medium (40-60%)"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"initial-public-offering-ipo",children:"Initial Public Offering (IPO)"}),"\n",(0,r.jsx)(n.h4,{id:"public-market-readiness",children:"Public Market Readiness"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Revenue Threshold"}),": $100M+ annual revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Growth Rate"}),": 30%+ annual growth"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Profitability"}),": Positive EBITDA or clear path to profitability"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Market Conditions"}),": Favorable biotech/healthcare IPO environment"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"ipo-valuation",children:"IPO Valuation"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Revenue Multiple"}),": 6-12x revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Market Cap Range"}),": $600M - $1.2B"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Timeline"}),": 6-8 years from Series A"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Probability"}),": Medium (30-50%)"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"ipo-requirements",children:"IPO Requirements"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Reporting"}),": SOX compliance and audited financials"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Corporate Governance"}),": Independent board and committees"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Operational Scale"}),": Mature operations and management"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Market Position"}),": Clear competitive advantages"]}),"\n"]}),"\n",(0,r.jsx)(n.h2,{id:"exit-timeline-and-milestones",children:"Exit Timeline and Milestones"}),"\n",(0,r.jsx)(n.h3,{id:"years-1-2-foundation-building",children:"Years 1-2: Foundation Building"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Focus"}),": Product development and market validation"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Milestones"}),": Revenue growth, customer acquisition, team building"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Exit Preparation"}),": None (too early)"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Valuation"}),": $15M - $75M"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"years-3-4-market-expansion",children:"Years 3-4: Market Expansion"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Focus"}),": Geographic expansion and product portfolio growth"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Milestones"}),": $20M+ revenue, market leadership position"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Exit Preparation"}),": Strategic relationship building"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Valuation"}),": $100M - $300M"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"years-5-6-scale-and-optimization",children:"Years 5-6: Scale and Optimization"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Focus"}),": Profitability and operational excellence"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Milestones"}),": $50M+ revenue, positive EBITDA"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Exit Preparation"}),": Active exit process initiation"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Valuation"}),": $300M - $600M"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"years-7-8-exit-execution",children:"Years 7-8: Exit Execution"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Focus"}),": Exit process management and value maximization"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Milestones"}),": $100M+ revenue, multiple exit options"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Exit Preparation"}),": Formal sale process or IPO preparation"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Valuation"}),": $500M - $1B+"]}),"\n"]}),"\n",(0,r.jsx)(n.h2,{id:"valuation-analysis",children:"Valuation Analysis"}),"\n",(0,r.jsx)(n.h3,{id:"revenue-based-valuation",children:"Revenue-Based Valuation"}),"\n",(0,r.jsx)(n.h4,{id:"current-market-multiples",children:"Current Market Multiples"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Public Biotech Companies"}),": 6-15x revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Private Biotech Companies"}),": 3-8x revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Specialty Pharma"}),": 4-10x revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Healthcare Services"}),": 2-6x revenue"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"company-specific-factors",children:"Company-Specific Factors"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Growth Rate"}),": Higher growth commands premium multiples"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Profitability"}),": EBITDA positive companies trade at higher multiples"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Market Position"}),": Market leaders receive valuation premiums"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Technology"}),": Proprietary technology increases valuation"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"comparable-company-analysis",children:"Comparable Company Analysis"}),"\n",(0,r.jsx)(n.h4,{id:"public-company-comparables",children:"Public Company Comparables"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Peptide Therapeutics"}),": 8-12x revenue multiples"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Specialty Pharma"}),": 6-10x revenue multiples"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Biotech Services"}),": 4-8x revenue multiples"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Healthcare Technology"}),": 10-20x revenue multiples"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"private-company-transactions",children:"Private Company Transactions"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Recent Acquisitions"}),": 4-8x revenue multiples"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Premiums"}),": 20-40% above trading multiples"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Synergy Value"}),": Additional 10-30% for strategic fit"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Competitive Bidding"}),": 15-25% premium in auction processes"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"dcf-valuation-model",children:"DCF Valuation Model"}),"\n",(0,r.jsx)(n.h4,{id:"key-assumptions",children:"Key Assumptions"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Revenue Growth"}),": 25-50% annually through exit"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"EBITDA Margins"}),": 25-35% at maturity"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Terminal Growth"}),": 3-5% long-term"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Discount Rate"}),": 12-15% (risk-adjusted)"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"valuation-range",children:"Valuation Range"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Conservative"}),": $400M - $600M"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Base Case"}),": $600M - $900M"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Optimistic"}),": $900M - $1.2B"]}),"\n"]}),"\n",(0,r.jsx)(n.h2,{id:"strategic-buyer-analysis",children:"Strategic Buyer Analysis"}),"\n",(0,r.jsx)(n.h3,{id:"pharmaceutical-companies-1",children:"Pharmaceutical Companies"}),"\n",(0,r.jsx)(n.h4,{id:"novartis",children:"Novartis"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Fit"}),": Strong peptide portfolio and expertise"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Acquisition History"}),": Active in specialty therapeutics"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Capacity"}),": $50B+ annual revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Synergy Potential"}),": High (distribution, R&D, manufacturing)"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"pfizer",children:"Pfizer"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Fit"}),": Expanding specialty care portfolio"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Acquisition History"}),": Large and mid-cap acquisitions"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Capacity"}),": $80B+ annual revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Synergy Potential"}),": High (global reach, regulatory expertise)"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"johnson--johnson",children:"Johnson & Johnson"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Fit"}),": Consumer and pharmaceutical synergies"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Acquisition History"}),": Innovation-focused acquisitions"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Capacity"}),": $90B+ annual revenue"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Synergy Potential"}),": Medium-High (consumer health crossover)"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"private-equity-firms",children:"Private Equity Firms"}),"\n",(0,r.jsx)(n.h4,{id:"kkr-healthcare-growth",children:"KKR (Healthcare Growth)"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Investment Focus"}),": Healthcare growth companies"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Portfolio Companies"}),": Complementary healthcare assets"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Capacity"}),": $400B+ assets under management"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Value Creation"}),": Operational improvement and consolidation"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"blackstone-life-sciences",children:"Blackstone (Life Sciences)"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Investment Focus"}),": Life sciences and healthcare"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Portfolio Strategy"}),": Platform building and add-on acquisitions"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Capacity"}),": $900B+ assets under management"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Value Creation"}),": Scale and operational excellence"]}),"\n"]}),"\n",(0,r.jsx)(n.h2,{id:"exit-process-management",children:"Exit Process Management"}),"\n",(0,r.jsx)(n.h3,{id:"preparation-phase-12-18-months",children:"Preparation Phase (12-18 months)"}),"\n",(0,r.jsx)(n.h4,{id:"financial-preparation",children:"Financial Preparation"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Audited Financials"}),": Clean financial statements and records"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Management Reporting"}),": Comprehensive KPI tracking"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Projections"}),": Detailed 3-5 year financial forecasts"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Working Capital"}),": Optimized balance sheet structure"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"operational-preparation",children:"Operational Preparation"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Management Team"}),": Complete and experienced leadership"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Systems & Processes"}),": Scalable operational infrastructure"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Quality Assurance"}),": Robust compliance and quality systems"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Customer Diversification"}),": Reduced customer concentration"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"legal-preparation",children:"Legal Preparation"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Corporate Structure"}),": Clean cap table and governance"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"IP Protection"}),": Comprehensive intellectual property portfolio"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Regulatory Compliance"}),": Full regulatory compliance documentation"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Contract Review"}),": Key customer and supplier agreements"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"marketing-phase-6-9-months",children:"Marketing Phase (6-9 months)"}),"\n",(0,r.jsx)(n.h4,{id:"investment-banking-selection",children:"Investment Banking Selection"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Bulge Bracket"}),": Goldman Sachs, Morgan Stanley, J.P. Morgan"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Healthcare Specialists"}),": Jefferies, Guggenheim, Cowen"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Boutique Firms"}),": Specialized healthcare investment banks"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Selection Criteria"}),": Industry expertise, relationships, execution capability"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"marketing-materials",children:"Marketing Materials"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Confidential Information Memorandum"}),": Comprehensive company overview"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Management Presentation"}),": Executive summary and key highlights"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Model"}),": Detailed projections and assumptions"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Due Diligence Materials"}),": Comprehensive data room preparation"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"buyer-outreach",children:"Buyer Outreach"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Buyers"}),": Direct outreach to target acquirers"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Buyers"}),": Private equity and growth capital firms"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"International Buyers"}),": Global pharmaceutical and biotech companies"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Competitive Process"}),": Managed auction to maximize value"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"execution-phase-3-6-months",children:"Execution Phase (3-6 months)"}),"\n",(0,r.jsx)(n.h4,{id:"due-diligence-management",children:"Due Diligence Management"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Data Room"}),": Comprehensive document repository"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Management Presentations"}),": Buyer meetings and Q&A sessions"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Site Visits"}),": Facility tours and operational reviews"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Reference Calls"}),": Customer and partner testimonials"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"negotiation-and-closing",children:"Negotiation and Closing"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Letter of Intent"}),": Initial terms and structure"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Purchase Agreement"}),": Detailed transaction documentation"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Regulatory Approvals"}),": Antitrust and regulatory clearances"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Closing Conditions"}),": Satisfaction of closing requirements"]}),"\n"]}),"\n",(0,r.jsx)(n.h2,{id:"value-maximization-strategies",children:"Value Maximization Strategies"}),"\n",(0,r.jsx)(n.h3,{id:"strategic-positioning",children:"Strategic Positioning"}),"\n",(0,r.jsx)(n.h4,{id:"market-leadership",children:"Market Leadership"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Market Share"}),": Establish dominant market position"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Brand Recognition"}),": Build strong brand and reputation"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Customer Loyalty"}),": Develop sticky customer relationships"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Competitive Moats"}),": Create sustainable competitive advantages"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"financial-performance",children:"Financial Performance"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Revenue Growth"}),": Demonstrate consistent growth trajectory"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Profitability"}),": Achieve positive EBITDA and cash flow"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Margins"}),": Maintain healthy gross and operating margins"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Predictability"}),": Build recurring revenue streams"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"operational-excellence",children:"Operational Excellence"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Scalability"}),": Demonstrate ability to scale operations"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Quality Systems"}),": Maintain high quality and compliance standards"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Technology Platform"}),": Invest in scalable technology infrastructure"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Team Strength"}),": Build experienced and capable management team"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"timing-optimization",children:"Timing Optimization"}),"\n",(0,r.jsx)(n.h4,{id:"market-conditions",children:"Market Conditions"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Industry Trends"}),": Favorable peptide therapy market dynamics"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"M&A Activity"}),": Active acquisition environment"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Public Markets"}),": Strong biotech/healthcare valuations"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Economic Environment"}),": Stable macroeconomic conditions"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"company-readiness",children:"Company Readiness"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Performance"}),": Strong revenue and profitability trends"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Position"}),": Clear competitive advantages and market position"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Management Team"}),": Complete and experienced leadership"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Growth Trajectory"}),": Clear path for continued growth"]}),"\n"]}),"\n",(0,r.jsx)(n.h2,{id:"risk-mitigation",children:"Risk Mitigation"}),"\n",(0,r.jsx)(n.h3,{id:"exit-risk-factors",children:"Exit Risk Factors"}),"\n",(0,r.jsx)(n.h4,{id:"market-risks",children:"Market Risks"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Industry Downturn"}),": Reduced M&A activity and valuations"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Regulatory Changes"}),": Adverse regulatory developments"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Competition"}),": Increased competitive pressure"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Economic Recession"}),": Reduced buyer appetite and valuations"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"company-specific-risks",children:"Company-Specific Risks"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Performance"}),": Missing growth or profitability targets"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Key Personnel"}),": Loss of critical management team members"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Customer Concentration"}),": Over-reliance on major customers"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Quality Issues"}),": Product quality or safety problems"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"mitigation-strategies",children:"Mitigation Strategies"}),"\n",(0,r.jsx)(n.h4,{id:"diversification",children:"Diversification"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Multiple Exit Options"}),": Maintain strategic and financial buyer options"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Geographic Diversification"}),": International market presence"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Product Portfolio"}),": Diversified product and service offerings"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Customer Base"}),": Broad and diversified customer relationships"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"contingency-planning",children:"Contingency Planning"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Alternative Scenarios"}),": Multiple exit timing and structure options"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Bridge Financing"}),": Access to additional capital if needed"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Management Retention"}),": Key personnel retention programs"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Operational Flexibility"}),": Ability to adjust operations as needed"]}),"\n"]}),"\n",(0,r.jsx)(n.h2,{id:"post-exit-considerations",children:"Post-Exit Considerations"}),"\n",(0,r.jsx)(n.h3,{id:"stakeholder-alignment",children:"Stakeholder Alignment"}),"\n",(0,r.jsx)(n.h4,{id:"investor-returns",children:"Investor Returns"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Return Expectations"}),": Meet or exceed investor return targets"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Distribution Timeline"}),": Efficient capital distribution process"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Tax Optimization"}),": Structure for optimal tax treatment"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Reinvestment Opportunities"}),": Follow-on investment options"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"management-team",children:"Management Team"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Retention Incentives"}),": Post-closing employment and incentives"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Equity Participation"}),": Management rollover equity opportunities"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Career Development"}),": Leadership roles in combined entity"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Non-Compete Agreements"}),": Reasonable post-closing restrictions"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"employee-considerations",children:"Employee Considerations"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Employment Continuity"}),": Job security and career opportunities"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Compensation"}),": Competitive compensation and benefits"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Culture Integration"}),": Smooth cultural integration process"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Equity Participation"}),": Employee equity value realization"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"integration-planning",children:"Integration Planning"}),"\n",(0,r.jsx)(n.h4,{id:"strategic-acquisitions",children:"Strategic Acquisitions"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Integration Planning"}),": Detailed post-closing integration plan"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Synergy Realization"}),": Clear synergy identification and capture"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Cultural Integration"}),": Smooth organizational integration"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Customer Retention"}),": Maintain customer relationships and satisfaction"]}),"\n"]}),"\n",(0,r.jsx)(n.h4,{id:"financial-buyers",children:"Financial Buyers"}),"\n",(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Growth Strategy"}),": Continued growth and expansion plans"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Operational Improvements"}),": Value creation initiatives"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Add-On Acquisitions"}),": Platform for additional acquisitions"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Exit Strategy"}),": Future exit planning and preparation"]}),"\n"]}),"\n",(0,r.jsx)(n.h2,{id:"next-steps",children:"Next Steps"}),"\n",(0,r.jsx)(n.h3,{id:"immediate-actions-next-12-months",children:"Immediate Actions (Next 12 Months)"}),"\n",(0,r.jsxs)(n.ol,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Systems"}),": Implement robust financial reporting and controls"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Management Team"}),": Complete senior management team"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Operational Excellence"}),": Optimize operations and quality systems"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Relationships"}),": Build relationships with potential acquirers"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Legal Structure"}),": Clean up corporate structure and governance"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"medium-term-preparation-years-2-3",children:"Medium-Term Preparation (Years 2-3)"}),"\n",(0,r.jsxs)(n.ol,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Market Position"}),": Establish market leadership position"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Financial Performance"}),": Achieve profitability and strong growth"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Investment Banking"}),": Select and engage investment banking advisor"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Due Diligence"}),": Prepare comprehensive due diligence materials"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Strategic Options"}),": Evaluate and develop multiple exit options"]}),"\n"]}),"\n",(0,r.jsx)(n.h3,{id:"exit-execution-years-4-5",children:"Exit Execution (Years 4-5)"}),"\n",(0,r.jsxs)(n.ol,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Process Launch"}),": Initiate formal exit process"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Buyer Outreach"}),": Engage strategic and financial buyers"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Due Diligence"}),": Manage buyer due diligence process"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Negotiation"}),": Negotiate optimal terms and structure"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Closing"}),": Execute transaction and distribute proceeds"]}),"\n"]})]})}function h(e={}){const{wrapper:n}={...(0,l.R)(),...e.components};return n?(0,r.jsx)(n,{...e,children:(0,r.jsx)(d,{...e})}):d(e)}},8453:(e,n,i)=>{i.d(n,{R:()=>t,x:()=>a});var s=i(6540);const r={},l=s.createContext(r);function t(e){const n=s.useContext(l);return s.useMemo(function(){return"function"==typeof e?e(n):{...n,...e}},[n,e])}function a(e){let n;return n=e.disableParentContext?"function"==typeof e.components?e.components(r):e.components||r:t(e.components),s.createElement(l.Provider,{value:n},e.children)}}}]);